CVM · CEL-SCI Corporation

CEL-SCI Corporation operates in the high-growth immunotherapy market, positioning Multikine as a first-line treatment administered pre-surgery for newly diagnosed advanced primary squamous cell carcinoma of the head and neck in patients with low PD-L1 expression and no lymph node involvement via PET. Phase 3 data presented at ESMO 2023 revealed compelling results in this target population: 73% five-year survival versus 45% in controls, a hazard ratio of 0.35 (95% CI 0.18-0.66), and significant pre-surgical tumor reductions/downstaging rates, supporting a planned 212-patient confirmatory registration study after FDA clearance. This addresses an unmet need in ~100,000 annual patients underserved by post-surgical checkpoint inhibitors like Keytruda, which favor high PD-L1 tumors. The company holds orphan drug designation from FDA, enhancing potential exclusivity if approved first.

Financially, CEL-SCI reports ongoing losses with $25.4M net loss for FY 2025 and $6.3M cash at December 31, 2025, burning through funds amid no revenue as a clinical-stage biotech. Auditors flag substantial going concern doubts tied to losses and regulatory uncertainties, compounded by material weaknesses in internal controls disclosed in the 10-K. This S-1/A best-efforts offering via ThinkEquity seeks ~$13.7M net at $3.07/share for up to 4.9M shares or equivalent pre-funded warrants (exercise $0.0001, no expiry, 4.99%/9.99% ownership cap), with no minimum commitment heightening execution risk—proceeds fund the confirmatory study and operations, but shortfalls could delay timelines critically.

Dilution is stark: pre-offering net tangible book value of $1.37/share rises to $1.91 post-offering, but new investors face $1.16 immediate dilution. Outstanding options (710k shares, $151.92 avg exercise) and warrants (36k shares, $94.76 avg) pose overhang, though high strikes limit near-term pressure. Management lock-ups (45 days for insiders, 30 days company-wide) provide short-term stability, but broad discretion on proceeds use relies on CEO Geert Kersten's judgment amid no dividend policy.

Key risks center on confirmatory study success, as Phase 3 retrospective subset analysis, while balanced per bias check, carries regulatory scrutiny; bridging study for PD-L1 companion diagnostic and CRO dependencies add delays. International efforts (SFDA Breakthrough Designation in Saudi Arabia) face geopolitical/trade risks. With 8.5M shares outstanding pre-offering on NYSE American (CVM), this capital raise is pivotal for survival and potential accelerated approval pathways via FDA/EMA conditional routes, but failure risks insolvency in this speculative biotech.